Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 6;15(4):540-550.
doi: 10.1093/ecco-jcc/jjaa205.

Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study

Mohamed Attauabi  1   2   3 , Anja Poulsen  4 , Klaus Theede  1   2 , Natalia Pedersen  5 , Lone Larsen  6 , Tine Jess  6   7 , Malte Rosager Hansen  8 , Marianne Kajbæk Verner-Andersen  9 , Kent V Haderslev  10 , Anders Berg Lødrup  11 , Akbar Molazahi  12 , Anders Neumann  13 , Abdel Wase  13 , Jakob Benedict Seidelin  4 , Johan Burisch  1   2
Affiliations

Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study

Mohamed Attauabi et al. J Crohns Colitis. .

Erratum in

Abstract

Background and aims: As no population-based study has investigated the susceptibility and disease course of COVID-19 among patients with inflammatory bowel diseases [IBD], we aimed to investigate this topic in a population-based setting.

Methods: Two cohorts were investigated. First, a nationwide cohort of all IBD patients diagnosed with COVID-19 was prospectively followed to investigate the disease courses of both diseases. Second, within a population-based cohort of 2.6 million Danish citizens, we identified all individuals tested for SARS-CoV-2 to determine the occurrence of COVID-19 among patients with and without IBD and other immune-mediated inflammatory diseases [IMIDs].

Results: Between January 28, 2020 and June 2, 2020, a total of 76 IBD patients with COVID-19 were identified in the national cohort and prospectively followed for 35 days (interquartile range [IQR]: 25-51). A large proportion [n = 19: 25%] required a COVID-19-related hospitalisation for 7 days [IQR: 2-8.5] which was associated with being 65 years or older (odds ratio [OR] = 23].80, 95% confidence interval [CI] 6.32-89.63, p <0.01) and presence of any non-IMID comorbidity [OR = 8.12, 95% CI 2.55-25.87, p <0.01], but not use of immunomodulators [p = 0.52] or biologic therapies [p = 0.14]. In the population-based study, 8476 of 231 601 [3.7%] residents tested positive for SARS-CoV-2; however, the occurrence was significantly lower among patients with IBD [62 of the 2486 patients = 2.5%, p <0.01] and other IMIDs [531 of 16 492 patients = 3.2%, p <0.01] as compared with patients without IMIDs.

Conclusions: Patients with IMIDs, including IBD, had a significantly lower susceptibility to COVID-19 than patients without IMIDs, and neither immunosuppressive therapies nor IBD activity were associated with the disease course of COVID-19.

Keywords: COVID-19; disease course; immune-mediated inflammatory diseases; inflammatory bowel diseases; population-based.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proportion of SARS-CoV-2-positive patients with various immune-mediated inflammatory diseases [IMIDs].
Figure 2.
Figure 2.
Number of patients with immune-mediated inflammatory diseases testing positive with SARS-CoV-2 over time.
Figure 3.
Figure 3.
Number of patients with immune-mediated inflammatory diseases tested for SARS-CoV-2 over time.
See this image and copyright information in PMC

References

    1. Guan WJ, Ni ZY, Hu Y, et al. ; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. - PMC - PubMed
    1. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 2018;155:337–46.e10. - PubMed
    1. Zabana Y, Rodríguez L, Lobatón T, et al. Relevant infections in inflammatory bowel disease, and their relationship with immunosuppressive therapy and their effects on disease mortality. J Crohns Colitis 2019;13:828–37. - PubMed
    1. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalisation for infection in patients with autoimmune diseases. JAMA 2011;306:2331–9. - PMC - PubMed
    1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74. - PMC - PubMed